Ataraxis AI
New York, US · Founded 2022 · Delaware corporation · 7 known investors
Ataraxis develops AI foundation models that analyze multi-modal patient data, including pathology slide images, to assess cancer aggressiveness and predict recurrence risk and treatment response. Its first product, Ataraxis Breast, provides clinically validated prognostic and predictive tools for breast cancer patients and their physicians.
AI & Machine LearningBiotechHealthtech
Founders & leadership
Ataraxis AI was founded in 2022 by Jan Witowski and Krzysztof Geras.
JW
Jan WitowskiinCo-founder (physician-scientist)
KG
Krzysztof GerasCo-founder
Board
KR
Krish RamaduralBoard director
RG
Rohan GaneshananthanBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$20M disclosed across 1 round · 2024
▶$20MraisedJan 2025 · 8 investors · Other TechnologyRule 506(b)
▶$20MraisedJan 2025 · 8 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Krish RamaduralDirector
- Rohan GaneshananthanDirector
- Jan WitowskiExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapPredictive Oncology3 shared keywordsPredictive Oncology combines machine learning with data from a large privately held biobank of over 150,000 tumor samples and 3D in vitro tumor models to predict drug response for pre-clinical drug discovery. It also offers tumor drug-response testing and genomic profiling services to personalize cancer therapies, serving biopharma partners and clinical oncology.
Elion3 shared keywords
Companies competing with Ataraxis AI for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ataraxis AI do?
- Ataraxis develops AI foundation models that analyze multi-modal patient data, including pathology slide images, to assess cancer aggressiveness and predict recurrence risk and treatment response. Its first product, Ataraxis Breast, provides clinically validated prognostic and predictive tools for breast cancer patients and their physicians.
- Who founded Ataraxis AI?
- Ataraxis AI was founded by Jan Witowski, Krzysztof Geras in 2022.
- Who are Ataraxis AI's investors?
- Ataraxis AI's investors include AIX Ventures, Floating Point, Giant Ventures Global Llp, Obvious Ventures, Transpose Platform Management, Bertelsmann Investments, Founders Fund.
- How much funding has Ataraxis AI raised?
- Ataraxis AI has disclosed $20M raised across 1 round.
- Where is Ataraxis AI headquartered?
- Ataraxis AI is headquartered in New York, US.